Disc Medicine Monthly Analysis (March 2026)

Disc Medicine

NasdaqGM:IRON

$ 60,09

$-1,92 (-3,10%)

60,09 $

$-1,92 (-3,10%)

End-of-day quote: 03/27/2026

Disc Medicine Stock Value

Analysts currently see NasdaqGM:IRON at the level of Buy.

Buy

Disc Medicine Company Info

EPS Growth 5Y

-7,56%

Market Cap

$2,37 B

Long-Term Debt

$0,03 B

Short Interest

4,74%

Quarterly earnings

05/07/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2017

Industry

Health Care

Country

United States

ISIN Number

US2546041011

Website

http://www.discmedicine.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$100,00

66.42%

Last Update: 03/26/2026

Analysts: 12

Highest Price Target $128,00

Average Price Target $100,00

Lowest Price Target $75,00

In the last five quarters, Disc Medicine’s Price Target has risen from $42,45 to $64,33 - a 51,54% increase. Ten analysts predict that Disc Medicine’s share price will increase in the coming year, reaching $100,00. This would represent an increase of 66,42%.

Top growth stocks in the health care sector (5Y.)

What does Disc Medicine do?

Disc Medicine, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company focuses on advancing its proprietary product candidates that target disorders related to the production and function of red blood cells. Business Segments The company manages its operations as a single operating segment focused on the development and commercialization of innovative...

Business Segments

The company manages its operations as a single operating segment focused on the development and commercialization of innovative therapeutics. Within this segment, the company's clinical and preclinical development activities encompass a range of product candidates that seek to modify fundamental biological pathways linked to red blood cell formation and function.

The company's operational structure emphasizes collaboration among its research and clinical teams to streamline the development process for its product candidates. The company's focus on a holistic approach to drug development includes research and clinical trials but also an emphasis on the commercialization of successful product candidates. This strategic outlook enables the company to navigate the complexities of bringing new drugs to market while addressing the needs of patients and healthcare providers.

Business Strategy

The company's business strategy is predicated on the consistent advancement of its innovative product pipeline and the execution of a focused development plan that aligns with its mission of transforming patient care in hematological disorders. The company emphasizes rigorous scientific validation and a commitment to best practices in research and development. In pursuit of its strategy, the company seeks to foster partnerships with clinical researchers and academic institutions to leverage external expertise and innovation.

Moreover, the company prioritizes patient-centric approaches throughout its research processes, ensuring that insights from patients and healthcare providers are factored into product candidate development. This patient-focused strategy reinforces the company's goal of meeting unmet medical needs while ensuring that the therapeutic solutions it develops align with patient expectations and experiences.

Products and Services

The company specializes in the development of innovative therapies aimed at treating hematological disorders. The company has a portfolio of product candidates that focus on improving red blood cell function and addressing key contributors to anemia and other related conditions. The development pipeline includes advanced therapeutics that target specific biological pathways involved in erythropoiesis, the process of red blood cell production.

The company employs cutting-edge techniques in molecular biology and pharmacology to engineer its product candidates, ensuring that these therapies are based on solid scientific rationale and clinical evidence. The company engages in comprehensive preclinical studies, including in vitro and in vivo testing, to establish the pharmacokinetics, pharmacodynamics, and safety profiles of its product candidates before proceeding to clinical development.

In addition to research and development, the company is focused on the potential for commercialization of its therapies upon successful completion of clinical trials. The company is dedicated to understanding market dynamics and collaborating with stakeholders that include healthcare professionals, academic institutions, and patient organizations to facilitate the successful adoption of its therapies post-approval.

Geographical Markets Served

The company's primary market is concentrated in the United States and strategically in regions where hematological disorders are prevalent.

Customers

The company's customer base primarily comprises healthcare providers, including hospitals, clinics, and specialty pharmacies engaged in treating patients with hematological disorders. The company aims to establish a direct relationship with the medical community, ensuring that healthcare professionals have access to information about its product candidates, clinical data, and related educational resources.

The company also engages with patient advocacy groups and organizations focused on supporting individuals with blood-related health conditions, ensuring that the needs and experiences of patients are reflected in its research and development activities. The company is dedicated to building a broad network of stakeholders committed to advancing care in hematology.

Sales and Marketing

The company employs a strategic approach to marketing and distribution. The company is focused on building relationships with healthcare professionals and stakeholders in the medical field to facilitate the uptake of its therapies. The primary marketing strategy revolves around education, awareness, and engagement with healthcare providers who are core to the treatment decision-making process.

The company leverages a combination of traditional and digital marketing tactics to disseminate information about its product candidates, including clinical trial results and safety data. Additionally, the company attends medical conferences and engages in collaborations with academic institutions and patient advocacy groups to further enhance its visibility and outreach efforts.

By prioritizing direct engagement with healthcare professionals and organizations, the company aims to create a robust network that can facilitate the successful commercialization of its products upon approval.

Government Regulations

The company is committed to complying with regulations from agencies such as the Food and Drug Administration (FDA) in the United States, as well as other applicable regulatory bodies globally.

History

Disc Medicine, Inc. was founded in 2017.

Disc Medicine Questions and Answers

Which sectors generate sales and which are the top 3 markets?

I'm sorry, but I do not have specific revenue data for Disc Medicine, Inc. (NasdaqGM:IRON) for the year 2026. Disc Medicine is a biopharmaceutical company focusing on the development of therapies for hematologic disorders. Therefore, it is likely that their revenues mainly come from the healthc...

At which locations are the company’s products manufactured?

**Production Sites:** No specific information available (as of 2026) Disc Medicine, Inc. is a biopharmaceutical company that focuses on developing therapies for the treatment of hematologic disorders. As the company is primarily engaged in research and development, it is likely that it outsources t...

What strategy does Disc Medicine pursue for future growth?

**Focus on Rare Blood Disorders** **Expansion of the Clinical Pipeline** **Strategic Partnerships** Disc Medicine, Inc. is focusing on the development of therapies for rare blood disorders. The company is pursuing a strategy aimed at expanding its clinical pipeline to provide innovative treatme...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information on the commodities or materials that Disc Medicine, Inc. imports, nor from which countries they originate. Companies like Disc Medicine, operating in the biopharmaceutical sector, typically source commodities and materials such as chemical compo...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 10% in the field of hematology (2026) **Research Expenditure:** 25% of revenue (2025) **Patent Portfolio:** 15 active patents (2026) Disc Medicine, Inc. has gained a significant competitive advantage in the field of hematology through specialized research and develo...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 72% (2026) **Insider Buys/Sells:** Net insider sales of 1.5 million USD (2026) The institutional investor share at Disc Medicine, Inc. is 72%, indicating a strong trust from institutional investors in the company. These investors typically include pension funds, i...

What percentage market share does Disc Medicine have?

**Market share of Disc Medicine, Inc.:** Estimate: 3-5% (2026) **Major competitors and their market shares:** 1. **Pfizer Inc.** - 15% 2. **Roche Holding AG** - 12% 3. **Novartis AG** - 10% 4. **Johnson & Johnson** - 9% 5. **Merck & Co., Inc.** - 8% 6. **Amgen Inc.** - 7% 7. **Bristol-Myers...

Is Disc Medicine stock currently a good investment?

**Revenue Growth:** 18% (2025) **Research and Development Expenses:** 45% of Revenue (2025) **Cash Reserves:** $150 million USD (End of 2025) Disc Medicine, Inc. recorded a revenue growth of 18% in 2025, attributed to the successful development and marketing of new drugs. The company is heavily inv...

Does Disc Medicine pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (as of 2026) Disc Medicine, Inc. currently does not pay a dividend to its shareholders. The company is in a growth phase and reinvests its profits in research and development as well as in expanding its business activities. For companies in the biotechnology indus...

New support ticket

Explore

Disc Medicine Stock Value

Disc Medicine Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Disc Medicine do?

Disc Medicine Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Disc Medicine Stock Value

Disc Medicine Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Disc Medicine do?

Disc Medicine Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.